November 8, 2019 posted by

Piramal deal will give Abbott India size Piramal, who is the chairman of Piramal Healthcare, said “the valuation of about nine times shows the. It took four hours for Ajay Piramal to negotiate a whopping $ billion valuation for his generics business with Abbott. Just how did he pull it off. Abbott to pay $ billion for unit of India’s Piramal Disagreements over valuation have prevented more deals from getting done. Abbott.

Author: Gardaktilar Mazuru
Country: Mozambique
Language: English (Spanish)
Genre: Relationship
Published (Last): 26 December 2008
Pages: 339
PDF File Size: 12.22 Mb
ePub File Size: 12.57 Mb
ISBN: 166-9-67869-634-9
Downloads: 65415
Price: Free* [*Free Regsitration Required]
Uploader: Moogubei

Expensive legal battles with patent holders, higher regulatory scrutiny after charges of poor manufacturing quality, and increased competition in the generics space have compelled Indian pharmaceuticals firms to look for buyers.

Forbes India Magazine – Print

Food and Drug Administration charged the Indian company with numerous violations on quality and safety fronts, and banned some of its drugs. Abbott plans to fund the deal with cash on its balance sheet and said it would not change its earnings outlook for Wharton management professor Saikat Chaudhuri says the relatively higher valuation makes sense for Abbott. To see abnott saved stories, click on link hightlighted in bold.

Piramal Healthcare also retains custom manufacturing, over-the-counter consumer products, diagnostic medical devices and services and clinical research, among other activities. Abbott and other Big Pharma companies face the twin challenges of slow growth in the developed markets and maturing product pipelines that are getting harder to replenish with newer, blockbuster drugs, according to Chaudhuri.

This is no different for Chinese firms.

Chaudhuri acknowledges those new realities, but with a patriotic tinge. Many view private equity firms as villainous actors intent on the singular goal of profit. The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in The potential to expand abbottt very high priced specialty products is seriously limited.


Abbott to pay 17K crore for Piramal generics business – The Economic Times

Its other businesses include third-party manufacturing and pathology laboratories. Your Reason has been Reported to the admin. The Abbott-Piramal deal is the latest in a wave of consolidation within the global pharmaceutical industry over the past few years. Mexico, for example, is in the process of changing its regime to require generics to be bioequivalent, she says.

valiation These other players are not even interested in doing that. Sumeet ChatterjeeBharghavi Nagaraju. Shares in Mumbai-based Piramal closed India certainly offers a large and growing domestic market with rising incomes and increasing health insurance coverage, says Danzon.

Increased funding expands the scope for drug research, but that alone is not enough; other pieces have to fall in place, Piramal notes. Danzon adds that the emerging business plan for generics companies is essentially around selling to pharmacists, not physicians. Fill in your details: Foul language Slanderous Inciting hatred against a certain community Others. Growth Through Overseas Expansion Globalization is not just for manufacturers.

Several other deals occurred over the past one year. In the piramao few years, they have realized that those pipelines are running dry, and are trying to diversify. Sign up for the weekly Knowledge Wharton e-mail newsletter, offering business leaders cutting-edge research and ideas from Wharton faculty and other experts. Food and Drug Administration said in February Ranbaxy sold misbranded or adulterated drugs in the United States, its largest market, having earlier banned imports of over 30 generic drugs from the firm.

BOis booming as governments battle rising healthcare costs. Abbott said it was advised by Morgan Stanley, while Piramal said it did not have a financial advisor on the valuatkon. Of its brands sold on Friday, at least 48 have sales of more than Rs 10 crore a year and are marketed by a sales force of 4, who reach more than 2. Based in Abbott Park, Ill. Disagreements over valuation have prevented more deals from getting done. Will be displayed Will not be displayed Will be displayed.


Find this comment offensive? As part of the deal, around 5, Piramal employees and one manufacturing facility in Baddi, Himachal Pradesh will be transferred to Abbott. There are a limited number of Indian generics companies that are attractive, and there might be considerable competition for them. This will alert our moderators to take action.

Abbott snaps up Piramal’s formulations biz for $3.7 bn

Read more on Piramal. As a global MNC, Piramql does. This will alert our moderators to take action Name Reason for reporting: Country Garden, one of the largest and most successful vertically integrated real estate[…]. It is not so much a concern about the downside, but about how we maximize the opportunity. It is increasingly a preferred choice for infrastructure and real estate developers as well. Get instant notifications from Economic Times Allow Not piiramal You can switch off notifications anytime using browser settings.

Drag according to your convenience. Never miss a great news story! Industry forecaster IMS Health predicts vakuation emerging markets will show annual pharmaceuticals sales growth of 14 to 17 percent throughagainst just 3 to 6 percent a year for developed markets.